

David A Henry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8586131/publications.pdf>

Version: 2024-02-01

305
papers

38,651
citations

19608

61
h-index

3257

185
g-index

315
all docs

315
docs citations

315
times ranked

42116
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of COVID-19 vaccines: findings from real-world studies. Medical Journal of Australia, 2022, 216, 431-431.	0.8	3
2	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. PLoS ONE, 2022, 17, e0269482.	1.1	5
3	Repeat testing for SARS-CoV-2: persistence of viral RNA is common, and clearance is slower in older people. Medical Journal of Australia, 2021, 214, 468-470.	0.8	6
4	Building a Systematic Online Living Evidence Summary of COVID-19 Research. Journal of the European Association for Health Information and Libraries, 2021, 17, 21-26.	0.2	1
5	Effectiveness of COVID-19 vaccines: findings from real world studies. Medical Journal of Australia, 2021, 215, 149.	0.8	56
6	Antihypertensive drugs and COVID-19. Heart, 2021, 107, 85.1-85.	1.2	0
7	Generating Real-World Evidence on the Quality Use, Benefits and Safety of Medicines in Australia: History, Challenges and a Roadmap for the Future. International Journal of Environmental Research and Public Health, 2021, 18, 13345.	1.2	11
8	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiology and Drug Safety, 2020, 29, 3-7.	0.9	28
9	The Canadian Network for Observational Drug Effect Studies (CNODES): Reflections on the first eight years, and a look to the future. Pharmacoepidemiology and Drug Safety, 2020, 29, 103-107.	0.9	15
10	How do trainee doctors learn about research? Content analysis of Australian specialist colleges' intended research curricula. BMJ Open, 2020, 10, e034962.	0.8	10
11	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2020, 60, 840-851.	0.4	36
12	Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 1927-1936.	6.3	224
13	Identifying the most effective essential medicines policies for quality use of medicines: A replicability study using three World Health Organisation data-sets. PLoS ONE, 2020, 15, e0228201.	1.1	7
14	Association between the regional variation in premature mortality and immigration in Ontario, Canada. Canadian Journal of Public Health, 2020, 111, 322-332.	1.1	1
15	Title is missing!. , 2020, 15, e0228201.		0
16	Title is missing!. , 2020, 15, e0228201.		0
17	Title is missing!. , 2020, 15, e0228201.		0
18	Title is missing!. , 2020, 15, e0228201.		0

#	ARTICLE	IF	CITATIONS
19	Regional variation of premature mortality in Ontario, Canada: a spatial analysis. <i>Population Health Metrics</i> , 2019, 17, 9.	1.3	15
20	Population risk and burden of health behavioralâ€“related all-cause, premature, and amenable deaths in Ontario, Canada: Canadian Community Health Surveyâ€“linked mortality files. <i>Annals of Epidemiology</i> , 2019, 32, 49-57.e3.	0.9	14
21	Burden of health behaviours and socioeconomic position on health care expenditure in Ontario. <i>F1000Research</i> , 2019, 8, 303.	0.8	4
22	Burden of health behaviours and socioeconomic position on health care expenditure in Ontario. <i>F1000Research</i> , 2019, 8, 303.	0.8	5
23	Response to authors re commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs. <i>International Journal of Epidemiology</i> , 2018, 47, 675-676.	0.9	0
24	Commentary: Renewed controversy over cardiovascular risk with non-steroidal anti-inflammatory drugs. <i>International Journal of Epidemiology</i> , 2018, 47, 362-367.	0.9	2
25	Trends and uptake of new formulations of controlled-release oxycodone in Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 520-525.	0.9	6
26	Characterising violent deaths of undetermined intent: a population-based study, 1999â€“2012. <i>Injury Prevention</i> , 2018, 24, 424-430.	1.2	13
27	Assessment of Long-term Follow-up of Randomized Trial Participants by Linkage to Routinely Collected Data. <i>JAMA Network Open</i> , 2018, 1, e186019.	2.8	56
28	Walking the Path Together: Indigenous Health Data at ICES. <i>Healthcare Quarterly (Toronto, Ont)</i> , 2018, 20, 6-9.	0.3	7
29	Accumulation Of Chronic Conditions At The Time Of Death Increased In Ontario From 1994 To 2013. <i>Health Affairs</i> , 2018, 37, 464-472.	2.5	30
30	Promoting quality use of medicines in South-East Asia: reports from country situational analyses. <i>BMC Health Services Research</i> , 2018, 18, 526.	0.9	9
31	Access to routinely collected data for population health research: experiences in Canada and Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2018, 42, 430-433.	0.8	11
32	Regional Inequalities in All-Cause and Premature Mortality in Ontario. <i>HealthcarePapers</i> , 2018, 17, 28-34.	0.2	0
33	Unlocking First Nations health information through data linkage. <i>International Journal of Population Data Science</i> , 2018, 3, 450.	0.1	12
34	NSAIDs as a Cause of Morbidity and Mortality from Peptic Ulcer Complications in New South Wales. , 2018, , 255-260.		0
35	Protocol for a scoping review of post-trial extensions of randomised controlled trials using individually linked administrative and registry data. <i>BMJ Open</i> , 2017, 7, e013770.	0.8	4
36	Socioeconomic gradients in all-cause, premature and avoidable mortality among immigrants and long-term residents using linked death records in Ontario, Canada. <i>Journal of Epidemiology and Community Health</i> , 2017, 71, 625-632.	2.0	38

#	ARTICLE	IF	CITATIONS
37	Indigenous health data and the path to healing. <i>Lancet, The</i> , 2017, 390, 2022-2023.	6.3	57
38	Impact of restricting diagnostic imaging reimbursement for uncomplicated low back pain in Ontario: a population-based interrupted time series analysis. <i>CMAJ Open</i> , 2017, 5, E760-E767.	1.1	13
39	Big Data and Population Health. <i>Epidemiology</i> , 2017, 28, 759-762.	1.2	21
40	Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. <i>CMAJ Open</i> , 2017, 5, E800-E807.	1.1	25
41	AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. <i>BMJ: British Medical Journal</i> , 2017, 358, j4008.	2.4	4,681
42	A population-based study of homicide deaths in Ontario, Canada using linked death records. <i>International Journal for Equity in Health</i> , 2017, 16, 133.	1.5	12
43	Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool. <i>PLoS Medicine</i> , 2016, 13, e1001987.	3.9	47
44	The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics. <i>PLoS ONE</i> , 2016, 11, e0152020.	1.1	54
45	Sex ratios at birth after induced abortion. <i>Cmaj</i> , 2016, 188, E181-E190.	0.9	30
46	Narrowing mortality gap between men and women over two decades: a registry-based study in Ontario, Canada. <i>BMJ Open</i> , 2016, 6, e012564.	0.8	25
47	Male-biased infant sex ratios and patterns of induced abortion. <i>Cmaj</i> , 2016, 188, 640-641.	0.9	1
48	Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. <i>Cmaj</i> , 2016, 188, 723-730.	0.9	47
49	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 461-472.	1.1	35
50	Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. <i>JAMA Internal Medicine</i> , 2016, 176, 1464.	2.6	87
51	ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. <i>BMJ, The</i> , 2016, 355, i4919.	3.0	8,654
52	A 3-year study of high-cost users of health care. <i>Cmaj</i> , 2016, 188, 182-188.	0.9	206
53	Achieving the World Health Organization's vision for clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 223-227.	1.1	13
54	Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border. <i>CMAJ Open</i> , 2015, 3, E231-E235.	1.1	4

#	ARTICLE	IF	CITATIONS
55	Informatics: Make sense of health data. <i>Nature</i> , 2015, 527, 31-32.	13.7	22
56	Sensor fault diagnosis using a non-homogeneous high-order sliding mode observer with application to a transport aircraft. <i>IET Control Theory and Applications</i> , 2015, 9, 598-607.	1.2	48
57	Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1716-1722.	2.2	14
58	Sliding Mode Observers for Fault Estimation in Multisensor Avionics Systems. , 2015, , 323-341.		2
59	Liberating the data from clinical trials. <i>BMJ, The</i> , 2015, 351, h4601.	3.0	19
60	Using Evidence to Combat Overdiagnosis and Overtreatment: Evaluating Treatments, Tests, and Disease Definitions in the Time of Too Much. <i>PLoS Medicine</i> , 2014, 11, e1001655.	3.9	75
61	WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys. <i>PLoS Medicine</i> , 2014, 11, e1001724.	3.9	68
62	Prescription medicines: decision-making preferences of patients who receive different levels of public subsidy. <i>Health Expectations</i> , 2014, 17, 15-26.	1.1	4
63	An Active Fault-Tolerant Flight Control Strategy. <i>Advances in Industrial Control</i> , 2014, , 119-149.	0.4	1
64	Asthma and Chronic Obstructive Pulmonary Disease (COPD) Prevalence and Health Services Use in Ontario: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2014, 9, e95899.	1.1	10
65	Review and Basic Concepts. <i>Advances in Industrial Control</i> , 2014, , 5-27.	0.4	0
66	Supervisory fault-tolerant control with mutual performance optimization. <i>International Journal of Adaptive Control and Signal Processing</i> , 2013, 27, 251-279.	2.3	38
67	Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2013, 21, 50.	0.9	29
68	Use of Non-Steroidal Anti-Inflammatory Drugs That Elevate Cardiovascular Risk: An Examination of Sales and Essential Medicines Lists in Low-, Middle-, and High-Income Countries. <i>PLoS Medicine</i> , 2013, 10, e1001388.	3.9	288
69	The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high?. <i>Australian Health Review</i> , 2013, 37, 32.	0.5	15
70	Sex ratios among Canadian liveborn infants of mothers from different countries. <i>Cmaj</i> , 2012, 184, E492-E496.	0.9	41
71	Preventing overdiagnosis: how to stop harming the healthy. <i>BMJ, The</i> , 2012, 344, e3502-e3502.	3.0	512
72	The health services burden of heart failure: an analysis using linked population health data-sets. <i>BMC Health Services Research</i> , 2012, 12, 103.	0.9	63

#	ARTICLE	IF	CITATIONS
73	Public Payments to Physicians in Ontario Adjusted for Overhead Costs. <i>Healthcare Policy</i> , 2012, 8, 30-36.	0.3	7
74	What the public learns about screening and diagnostic tests through the media. <i>Medical Journal of Australia</i> , 2012, 197, 324-326.	0.8	8
75	A Prompt to the Web: The Media and Health Information Seeking Behaviour. <i>PLoS ONE</i> , 2012, 7, e34314.	1.1	36
76	CNODES: the Canadian Network for Observational Drug Effect Studies. <i>Open Medicine</i> , 2012, 6, e134-40.	1.5	52
77	Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion. <i>The Cochrane Library</i> , 2011, , CD004172.	1.5	20
78	Doctors and drug companies: Still cozy after all these years. <i>International Journal of Risk and Safety in Medicine</i> , 2011, 23, 7-10.	0.3	0
79	Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2011, , CD001886.		258
80	SUPERVISORY FAULT TOLERANT CONTROL BASED ON DWELL-TIME CONDITIONS. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2011, 44, 13717-13722.	0.4	0
81	The risk of coronary thrombosis with cyclooxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclooxygenase-2 gene. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 707-714.	1.1	6
82	Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. <i>PLoS Medicine</i> , 2011, 8, e1001098.	3.9	449
83	Lesson From Canada's Universal Care: Socially Disadvantaged Patients Use More Health Services, Still Have Poorer Health. <i>Health Affairs</i> , 2011, 30, 274-283.	2.5	49
84	Coverage with evidence development: The Ontario experience. <i>International Journal of Technology Assessment in Health Care</i> , 2011, 27, 159-168.	0.2	32
85	Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2011, , CD001886.		372
86	Using Linked Health Administrative Data to Assess the Clinical and Healthcare System Impact of Chronic Diseases in Ontario. <i>Healthcare Quarterly</i> , 2011, 14, 23-27.	0.7	18
87	Aging in Ontario: Using Population-Based Data in the Evaluation of Trends in Health System Use. <i>Healthcare Quarterly</i> , 2011, 14, 21-25.	0.7	6
88	Health Systems and Sustainability: Doctors and Consumers Differ on Threats and Solutions. <i>PLoS ONE</i> , 2011, 6, e19222.	1.1	14
89	What are the Roles and Responsibilities of the Media in Disseminating Health Information?. , 2011, , 197-213.		0
90	Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. , 2010, , CD002042.		100

#	ARTICLE	IF	CITATIONS
91	Cell salvage for minimising perioperative allogeneic blood transfusion. , 2010 , CD001888.		151
92	Aspirin use in children: heeding the warning?. Australian Journal of Public Health, 2010, 16, 35-37.	0.2	0
93	The efficiency frontier approach to economic evaluation of health care interventions. Health Economics (United Kingdom), 2010, 19, 1117-1127.	0.8	97
94	IQWiG methods " a response to two critiques. Health Economics (United Kingdom), 2010, 19, 1137-1138.	0.8	8
95	Attitudes of physicians and public to pharmaceutical industry "gifts"™. Internal Medicine Journal, 2010, 40, 335-341.	0.5	20
96	Deconstructing cancer: what makes a good quality news story?. Medical Journal of Australia, 2010, 193, 702-706.	0.8	6
97	Improved Outcomes With Early Collaborative Care of Ambulatory Heart Failure Patients Discharged From the Emergency Department. Circulation, 2010, 122, 1806-1814.	1.6	159
98	Doctors and Drug Companies: Still Cozy after All These Years. PLoS Medicine, 2010, 7, e1000359.	3.9	8
99	Does It Matter Who Writes Medical News Stories?. PLoS Medicine, 2010, 7, e1000323.	3.9	29
100	Cohort Profile: The Hunter Community Study. International Journal of Epidemiology, 2010, 39, 1452-1463.	0.9	106
101	Cell salvage for minimising perioperative allogeneic blood transfusion. , 2010 , CD001888.		180
102	Supervisory fault tolerant control via common lyapunov function approach. , 2010 , .		4
103	A FTC Strategy for Safe Recovery against Trimmable Horizontal Stabilizer Failure with Guaranteed Nominal Performance. Lecture Notes in Control and Information Sciences, 2010 , 337-361.	0.6	0
104	Media Reporting of Health Interventions: Signs of Improvement, but Major Problems Persist. PLoS ONE, 2009, 4, e4831.	1.1	80
105	A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj, 2009, 180, 713-718.	0.9	622
106	The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. Cmaj, 2009, 180, 183-193.	0.9	151
107	How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns: Table 1.. Journal of Rheumatology, 2009, 36, 2114-2121.	1.0	7
108	Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals. PLoS Medicine, 2009, 6, e1000128.	3.9	27

#	ARTICLE	IF	CITATIONS
109	Observations from the OMERACT Drug Safety Summit, May 2008. <i>Journal of Rheumatology</i> , 2009, 36, 2110-2113.	1.0	6
110	Increasing the demand for childhood vaccination in developing countries: a systematic review. <i>BMC International Health and Human Rights</i> , 2009, 9, S5.	2.5	54
111	AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 1013-1020.	2.4	1,427
112	Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. <i>Australian Health Review</i> , 2009, 33, 192.	0.5	23
113	Disease mongering: expanding the boundaries of treatable disease. <i>Internal Medicine Journal</i> , 2008, 38, 858-861.	0.5	27
114	Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 927-934.	1.1	27
115	Development of an Active Fault-Tolerant Flight Control Strategy. <i>Journal of Guidance, Control, and Dynamics</i> , 2008, 31, 135-147.	1.6	89
116	Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia. <i>Journal of Public Health Policy</i> , 2008, 29, 106-120.	1.0	14
117	Disease Mongering Is Now Part of the Global Health Debate. <i>PLoS Medicine</i> , 2008, 5, e106.	3.9	46
118	An Analysis of News Media Coverage of Complementary and Alternative Medicine. <i>PLoS ONE</i> , 2008, 3, e2406.	1.1	51
119	Ensuring the safety of new medications and devices: are naltrexone implants safe?. <i>Medical Journal of Australia</i> , 2008, 188, 438-439.	0.8	11
120	What Drives Health-Care Spending Priorities? An International Survey of Health-Care Professionals. <i>PLoS Medicine</i> , 2007, 4, e94.	3.9	10
121	Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 586.	3.8	1
122	Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. , 2007, , CD001886.		175
123	Selective COX-2 Inhibitors: A Promise Unfulfilled?. <i>Gastroenterology</i> , 2007, 132, 790-794.	0.6	25
124	A Quality Use of Medicines program for general practitioners and older people: a cluster randomised controlled trial. <i>Medical Journal of Australia</i> , 2007, 187, 23-30.	0.8	122
125	Evaluating medicines: let's use all the evidence. <i>Medical Journal of Australia</i> , 2007, 186, 249-252.	0.8	29
126	Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. <i>Medical Journal of Australia</i> , 2007, 187, 236-239.	0.8	17

#	ARTICLE	IF	CITATIONS
127	Global Pharmaceuticals: Ethics, Markets, Practices. Australian and New Zealand Journal of Public Health, 2007, 31, 91-92.	0.8	0
128	Patterns of analgesic and anti-inflammatory medicine use by Australian veterans. Internal Medicine Journal, 2007, 37, 798-805.	0.5	13
129	COX-2, NSAIDs, and cardiovascular risk. Current Cardiovascular Risk Reports, 2007, 1, 296-302.	0.8	0
130	The Fight against Disease Mongering: Generating Knowledge for Action. PLoS Medicine, 2006, 3, e191.	3.9	175
131	Cell salvage for minimising perioperative allogeneic blood transfusion. , 2006, , CD001888.		65
132	Pharmaceutical policies: effects on rational drug use. The Cochrane Library, 2006, , .	1.5	19
133	Pharmaceutical benefits scheme policy: confused and tough on patients. Internal Medicine Journal, 2006, 36, 211-213.	0.5	5
134	Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia. Internal Medicine Journal, 2006, 36, 571-578.	0.5	38
135	Cyclooxygenase-2 inhibitors and coronary occlusion â€œ exploring doseâ€œresponse relationships. British Journal of Clinical Pharmacology, 2006, 62, 358-365.	1.1	32
136	Gifts, Drug Samples, and other Items Given to Medical Specialists by Pharmaceutical Companies. Journal of Bioethical Inquiry, 2006, 3, 139-148.	0.9	7
137	Empirical uncertainty and moral contest: A qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia. Social Science and Medicine, 2006, 62, 1510-1519.	1.8	29
138	Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery. British Journal of Surgery, 2006, 93, 810-819.	0.1	144
139	Cardiovascular Risk and Inhibition of Cyclooxygenase. JAMA - Journal of the American Medical Association, 2006, 296, 1633.	3.8	966
140	Cost-effectiveness and Resource Allocationâ€œReply. JAMA - Journal of the American Medical Association, 2006, 295, 2723.	3.8	2
141	Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations. Internal Medicine Journal, 2005, 35, 206-210.	0.5	15
142	Blood transfusion and autologous donation: a survey of post-surgical patients, interest group members and the public. Transfusion Medicine, 2005, 15, 19-32.	0.5	15
143	Systematic review of autologous transfusion techniques. Transfusion Medicine, 2005, 15, 255-255.	0.5	0
144	Moral hazard and prescription medicine use in Australiaâ€œthe patient perspective. Social Science and Medicine, 2005, 60, 1437-1443.	1.8	29

#	ARTICLE	IF	CITATIONS
145	Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. <i>BMC Cardiovascular Disorders</i> , 2005, 5, 19.	0.7	54
146	Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience. <i>Medical Journal of Australia</i> , 2005, 182, 557-560.	0.8	43
147	Monitoring the quality of medical news reporting: early experience with media doctor. <i>Medical Journal of Australia</i> , 2005, 183, 190-193.	0.8	77
148	Ties That Bind. <i>Archives of Internal Medicine</i> , 2005, 165, 2493.	4.3	20
149	What Are the Roles and Responsibilities of the Media in Disseminating Health Information?. <i>PLoS Medicine</i> , 2005, 2, e215.	3.9	121
150	Medical Research and the News Media. <i>New England Journal of Medicine</i> , 2005, 352, 838-839.	13.9	0
151	Drug Prices and Value for Money. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2630.	3.8	94
152	Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. <i>Globalization and Health</i> , 2005, 1, 15.	2.4	20
153	The free trade agreement between Australia and the United States. <i>BMJ: British Medical Journal</i> , 2004, 328, 1271-1272.	2.4	18
154	Patient co-payments and use of prescription medicines. <i>Australian and New Zealand Journal of Public Health</i> , 2004, 28, 62-67.	0.8	25
155	Durable efficacy of metformin/glibenclamide* combination tablets (Glucovance®) during 52 weeks of open-label treatment in type 2 diabetic patients with hyperglycaemia despite previous sulphonylurea monotherapy. <i>International Journal of Clinical Practice</i> , 2004, 58, 820-826.	0.8	7
156	Autologous transfusion techniques: a systematic review of their efficacy. <i>Transfusion Medicine</i> , 2004, 14, 123-144.	0.5	149
157	Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. <i>BMC Health Services Research</i> , 2004, 4, 38.	0.9	883
158	Misleading drug promotion?no sign of improvements. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 797-799.	0.9	5
159	Pharmaceuticals, intellectual property and free trade: the case of the US's "Australia free trade agreement. <i>Prometheus</i> , 2004, 22, 243-257.	0.2	59
160	Single-Enantiomer Drugs. <i>Clinical Pharmacokinetics</i> , 2004, 43, 287-290.	1.6	45
161	Grading quality of evidence and strength of recommendations. <i>BMJ: British Medical Journal</i> , 2004, 328, 1490.	2.4	6,376
162	Describing treatment effects to patients. <i>Journal of General Internal Medicine</i> , 2003, 18, 948-959.	1.3	129

#	ARTICLE	IF	CITATIONS
163	Published pharmacoeconomic analyses: science or marketing?. Internal Medicine Journal, 2003, 33, 403-404.	0.5	6
164	Bridges to Iran. Lancet, The, 2003, 361, 438.	6.3	0
165	Patent law. Lancet, The, 2003, 361, 1059.	6.3	1
166	Platelet-rich-plasmapheresis for minimising peri-operative allogeneic blood transfusion. , 2003, , CD004172.		5
167	Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. The Cochrane Library, 2003, , CD004171.	1.5	62
168	Effect of computerised prescribing on use of antibiotics. Medical Journal of Australia, 2003, 178, 210-213.	0.8	25
169	Effect of computerised prescribing on use of antibiotics. Medical Journal of Australia, 2003, 179, 62-63.	0.8	0
170	The PBS community awareness campaign: how helpful is blaming patients?. Medical Journal of Australia, 2003, 179, 544-545.	0.8	11
171	Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. International Journal of Clinical Practice, Supplement, 2003, , 43-9.	0.3	36
172	Selling sickness: the pharmaceutical industry and disease mongering * Commentary: Medicalisation of risk factors. BMJ: British Medical Journal, 2002, 324, 886-891.	2.4	676
173	V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women. Endocrine Reviews, 2002, 23, 529-539.	8.9	329
174	The pharmaceutical industry and disease mongering. BMJ: British Medical Journal, 2002, 325, 216-216.	2.4	4
175	Differential pricing of drugs: a role for cost-effectiveness analysis?. Lancet, The, 2002, 359, 2105-2107.	6.3	34
176	The pharmaceutical industry as a medicines provider. Lancet, The, 2002, 360, 1590-1595.	6.3	133
177	Drug advertising: truths, half-truths and few statistics. Medical Journal of Australia, 2002, 177, 285-286.	0.8	3
178	Limitations of Health Insurance Commission (HIC) data for deriving prescribing indicators. Medical Journal of Australia, 2002, 176, 419-424.	0.8	15
179	Transfusion triggers: A systematic review of the literature*. Transfusion Medicine Reviews, 2002, 16, 187-199.	0.9	244
180	Systematic review of the use of fibrin sealant to minimize perioperative allogeneic blood transfusion. British Journal of Surgery, 2002, 89, 695-703.	0.1	88

#	ARTICLE	IF	CITATIONS
181	Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 201-208.	2.2	121
182	Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. <i>Diabetes, Obesity and Metabolism</i> , 2002, 4, 368-375.	2.2	58
183	Changes to the Pharmaceutical Benefits Advisory Committee. <i>Medical Journal of Australia</i> , 2001, 174, 209-210.	0.8	9
184	The impact of specialists on prescribing by general practitioners. <i>Medical Journal of Australia</i> , 2001, 175, 407-411.	0.8	31
185	Pre-operative autologous donation for minimising perioperative allogeneic blood transfusion. <i>The Cochrane Library</i> , 2001, , CD003602.	1.5	117
186	Personal formularies. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 333-341.	0.8	22
187	Factors influencing the uptake of technologies to minimize perioperative allogeneic blood transfusion: an interview study of national and institutional stakeholders. <i>Internal Medicine Journal</i> , 2001, 31, 230-236.	0.5	17
188	Drug information for consumers: should it be disease or medication specific? Results of a community survey. <i>Australian and New Zealand Journal of Public Health</i> , 2001, 25, 564-570.	0.8	30
189	The effects of increased rehabilitation therapy after brain injury: results of a prospective controlled trial. <i>Clinical Rehabilitation</i> , 2001, 15, 501-514.	1.0	107
190	Agreement between randomized and non-randomized studies: the effects of bias and confounding. <i>BMC News and Views</i> , 2001, 1, .	0.0	3
191	Renal and cardiovascular toxicity of non-steroidal anti-inflammatory drugs. <i>Inflammopharmacology</i> , 2000, 8, 1-18.	1.9	9
192	Problems With the Interpretation of Pharmacoeconomic Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 2116.	3.8	190
193	Recent changes in the profile of prescription NSAID use in Australia. <i>Medical Journal of Australia</i> , 2000, 172, 188-188.	0.8	5
194	Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. , 2000, , CD002042.		49
195	Specialist or generalist care? A study of the impact of a selective admitting policy for patients with cardiac failure. <i>International Journal for Quality in Health Care</i> , 2000, 12, 339-345.	0.9	19
196	Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients. <i>Archives of Internal Medicine</i> , 2000, 160, 777.	4.3	410
197	Short-Term Treatment with Zanamivir to Prevent Influenza: Results of a Placebo-Controlled Study. <i>Clinical Infectious Diseases</i> , 2000, 30, 587-589.	2.9	74
198	Coverage by the News Media of the Benefits and Risks of Medications. <i>New England Journal of Medicine</i> , 2000, 342, 1645-1650.	13.9	448

#	ARTICLE	IF	CITATIONS
199	Current Problems with Non-Specific COX Inhibitors. <i>Current Pharmaceutical Design</i> , 2000, 6, 1693-1724.	0.9	54
200	TECHNOLOGIES TO MINIMIZE BLOOD TRANSFUSION IN CARDIAC AND ORTHOPEDIC SURGERY. <i>International Journal of Technology Assessment in Health Care</i> , 1999, 15, 717-728.	0.2	46
201	Assessing new health technologies: lessons to be learned from drugs. <i>Medical Journal of Australia</i> , 1999, 171, 554-556.	0.8	6
202	Pharmacists' outreach visits and doctors' prescribing. <i>Medical Journal of Australia</i> , 1999, 170, 460-461.	0.8	0
203	Effects of information framing on the intentions of family physicians to prescribe long-term hormone replacement therapy. <i>Journal of General Internal Medicine</i> , 1999, 14, 591-598.	1.3	22
204	The effects of information framing on the practices of physicians. <i>Journal of General Internal Medicine</i> , 1999, 14, 633-642.	1.3	112
205	Meta-analysisâ€”its role in assessing drug safety. , 1999, 8, 167-168.		4
206	Cost-Effectiveness Analysis in the Treatment of Hypertension: A Medical View. <i>Clinical and Experimental Hypertension</i> , 1999, 21, 999-1008.	0.5	8
207	Pharmacoeconomics and policy decisions: The Australian health care system. <i>Clinical Therapeutics</i> , 1999, 21, 909-915.	1.1	5
208	Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. <i>BMJ: British Medical Journal</i> , 1999, 318, 507-511.	2.4	111
209	A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. <i>Climacteric</i> , 1998, 1, 112-123.	1.1	50
210	Evaluation of a Weight-Adjusted Single-Bolus Plasminogen Activator in Patients With Myocardial Infarction. <i>Circulation</i> , 1998, 98, 2117-2125.	1.6	92
211	Management and outcomes of congestive heart failure: a prospective study of hospitalised patients. <i>Medical Journal of Australia</i> , 1998, 168, 115-118.	0.8	40
212	â€œPharmaceutical securityâ€”a new research agenda. <i>Medical Journal of Australia</i> , 1998, 169, 262-263.	0.8	0
213	Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 85-90.	1.1	90
214	Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence-the Australian experience. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 421-425.	1.1	8
215	Meta-analysis of risk of gastrointestinal complications with NSAIDs. <i>BMJ: British Medical Journal</i> , 1997, 314, 445-445.	2.4	5
216	Editorial: Prescribing costs: whose responsibility?. <i>Australian Prescriber</i> , 1997, 20, 26-27.	0.5	3

#	ARTICLE	IF	CITATIONS
217	Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994 A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. Medical Journal of Australia, 1996, 164, 589-592.	0.8	35
218	Development of Hematopoietic Cancers After Implantation of Total Joint Replacement. Clinical Orthopaedics and Related Research, 1996, 329, S290-S296.	0.7	85
219	Prescription Drug Utilization Following Patient Co-Payment Changes in Australia. , 1996, 5, 385-392.		41
220	Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ: British Medical Journal, 1996, 312, 1563-1566.	2.4	680
221	Benzodiazepine Use as a Cause of Cognitive Impairment in Elderly Hospital Inpatients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1995, 50A, M99-M106.	1.7	128
222	Trial of streptokinase in ischaemic stroke. Lancet, The, 1995, 345, 1053.	6.3	0
223	Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ: British Medical Journal, 1995, 310, 897-901.	2.4	272
224	Promoting cost effective prescribing. BMJ: British Medical Journal, 1995, 310, 955-956.	2.4	39
225	Comparing treatments. BMJ: British Medical Journal, 1995, 310, 1279-1279.	2.4	33
226	Adverse drug reactions: Can consumers provide early warning?. Pharmacoepidemiology and Drug Safety, 1994, 3, 257-264.	0.9	21
227	Drugs as a cause of gastrointestinal disease. Bailliere's Clinical Gastroenterology, 1994, 8, 271-300.	0.9	5
228	Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet, The, 1994, 343, 159-162.	6.3	108
229	Toxicity of dothiepin in overdose. Lancet, The, 1994, 343, 735.	6.3	2
230	Flucloxacillin and cholestatic hepatitis. Medical Journal of Australia, 1994, 160, 525-525.	0.8	13
231	What do health care professionals know about childhood asthma?. Journal of Paediatrics and Child Health, 1993, 29, 32-35.	0.4	16
232	GASTROINTESTINAL HAEMORRHAGE. Lancet, The, 1993, 341, 527-528.	6.3	3
233	MENINGITIS. Lancet, The, 1993, 341, 530.	6.3	24
234	Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology, 1993, 105, 1078-1088.	0.6	276

#	ARTICLE	IF	CITATIONS
235	Nonsteroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales. <i>Gastroenterology</i> , 1993, 104, 1083-1091.	0.6	40
236	Erythromycin-associated Cholestatic Hepatitis. <i>Medical Journal of Australia</i> , 1993, 158, 600-602.	0.8	57
237	Cholestatic Hepatitis Associated with Flucloxacillin. <i>Medical Journal of Australia</i> , 1993, 158, 596-600.	0.8	66
238	Implications of the Australian Guidelines for the United States. <i>Health Affairs</i> , 1992, 11, 202-206.	2.5	6
239	Economic Analysis as an Aid to Subsidisation Decisions. <i>Pharmacoeconomics</i> , 1992, 1, 54-67.	1.7	109
240	Should Indirect Costs and Benefits be Included?. <i>Pharmacoeconomics</i> , 1992, 1, 462-462.	1.7	3
241	The Australian Guidelines for Subsidisation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1992, 2, 422-426.	1.7	12
242	Drug use in Australia: a community prevalence study. <i>Medical Journal of Australia</i> , 1992, 156, 759-764.	0.8	41
243	10. Meta-analysis: Part 2: assessing the quality of published meta-analyses. <i>Medical Journal of Australia</i> , 1992, 156, 173-187.	0.8	44
244	Effects of prior use of non-steroidal anti-inflammatory drugs on renal function and transfusion requirements after upper gastrointestinal haemorrhage. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 341-345.	0.8	2
245	CHANGING TRENDS IN PERFORATED PEPTIC ULCER DURING THE PAST 45 YEARS. <i>ANZ Journal of Surgery</i> , 1992, 62, 729-732.	0.3	11
246	PERFORATED PEPTIC ULCER IN THE HUNTER REGION: A REVIEW OF 174 CASES. <i>ANZ Journal of Surgery</i> , 1992, 62, 338-343.	0.3	11
247	Agreement between two measures of drug use in a low-prevalence population. <i>Addictive Behaviors</i> , 1991, 16, 507-516.	1.7	17
248	Pharmacoepidemiology as a focus for clinical epidemiology in developing countries. <i>Journal of Clinical Epidemiology</i> , 1991, 45, 101-105.	2.4	3
249	NSAIDs and risk of upper gastrointestinal bleeding. <i>Lancet</i> , The, 1991, 337, 730-731.	6.3	17
250	Recent trends in the prescribing of cholesterol lowering drugs in Australia A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. <i>Medical Journal of Australia</i> , 1991, 155, 332-336.	0.8	15
251	Meta-Analysis Workshop in Upper Gastrointestinal Hemorrhage. <i>Gastroenterology</i> , 1991, 100, 1481-1482.	0.6	10
252	Potential for Bias in Economic Analyses. <i>New England Journal of Medicine</i> , 1991, 325, 1384-1385.	13.9	1

#	ARTICLE	IF	CITATIONS
253	Diclofenac hepatitis.. Gut, 1991, 32, 1381-1385.	6.1	69
254	Plasma Noradrenaline, Platelet alpha2-Adrenoceptors, and Functional Scores during Ethanol Withdrawal. Alcoholism: Clinical and Experimental Research, 1990, 14, 497-502.	1.4	28
255	Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Medical Journal of Australia, 1989, 150, 329-331.	0.8	110
256	ENZYME INDUCTION BY EATING CHARCOAL-GRILLED STEAK WITH NO EFFECT ON BLOOD LIPIDS. Clinical and Experimental Pharmacology and Physiology, 1989, 16, 783-788.	0.9	3
257	Do patients understand asthma?. Medical Journal of Australia, 1989, 150, 226-226.	0.8	0
258	Adverse reactions to N-acetylcysteine. Medical Journal of Australia, 1989, 151, 300-302.	0.8	1
259	Side-effects of non-steroidal anti-inflammatory drugs. Bailliere's Clinical Rheumatology, 1988, 2, 425-454.	1.0	59
260	Endoscopic Coagulation for Gastrointestinal Bleeding. New England Journal of Medicine, 1988, 318, 185-188.	13.9	0
261	Epidemiological Assessment of the Association Between NSAIDS and Peptic Ulcer Complications. , 1988, 24, 85-94.		4
262	Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids.. BMJ: British Medical Journal, 1987, 295, 1227-1229.	2.4	108
263	Monitoring the safety of over the counter drugs.. BMJ: British Medical Journal, 1987, 295, 1414-1414.	2.4	1
264	Propranolol steady-state pharmacokinetics are unaltered by omeprazole. European Journal of Clinical Pharmacology, 1987, 33, 369-373.	0.8	55
265	Glucmannan and risk of oesophageal obstruction.. BMJ: British Medical Journal, 1986, 292, 591-592.	2.4	23
266	OMEPRAZOLE: EFFECTS ON OXIDATIVE DRUG METABOLISM IN THE RAT. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 377-381.	0.9	6
267	The likely impact on drug regulation in Australia. Medical Journal of Australia, 1986, 144, 256-258.	0.8	1
268	[14C]aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Digestive Diseases and Sciences, 1985, 30, 813-818.	1.1	45
269	Peptic ulcer and piroxicam. BMJ: British Medical Journal, 1985, 290, 1663-1664.	2.4	1
270	L-643.441: an H2-receptor antagonist with potent and long-lasting effects in man.. British Journal of Clinical Pharmacology, 1985, 20, 133-136.	1.1	3

#	ARTICLE	IF	CITATIONS
271	SOMATOSTATIN IN TREATMENT OF HAEMATEMESIS AND MELAENA. <i>Lancet, The</i> , 1985, 325, 130-132.	6.3	80
272	Rational choice of drugs for ulcer therapy. <i>Medical Journal of Australia</i> , 1984, 141, 726-727.	0.8	0
273	Parenteral aluminum administration in the dog: I. Plasma kinetics, tissue levels, calcium metabolism, and parathyroid hormone. <i>Kidney International</i> , 1984, 25, 362-369.	2.6	75
274	Parenteral aluminum administration in the dog: II. Induction of osteomalacia and effect on vitamin D metabolism. <i>Kidney International</i> , 1984, 25, 370-375.	2.6	107
275	Omeprazole: effects on oxidative drug metabolism.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 195-200.	1.1	49
276	INHIBITION OF DRUG METABOLISM BY OMEPRAZOLE. <i>Lancet, The</i> , 1984, 324, 46-47.	6.3	6
277	New drugs for peptic ulcer. <i>Medical Journal of Australia</i> , 1984, 141, 303-308.	0.8	6
278	Cimetidine and Tranexamic Acid in the Treatment of Acute Upper-Gastrointestinal-Tract Bleeding. <i>New England Journal of Medicine</i> , 1983, 308, 1571-1575.	13.9	152
279	Cimetidine and Tranexamic Acid for Upper-Gastrointestinal-Tract Bleeding. <i>New England Journal of Medicine</i> , 1983, 309, 1328-1328.	13.9	1
280	ARGON LASER PHOTOCOAGULATION IN BLEEDING PEPTIC ULCERS. <i>Lancet, The</i> , 1982, 319, 99.	6.3	1
281	EARLY EXPERIENCE WITH A VERTICAL SPINNING-DISC NEBULISER. <i>Lancet, The</i> , 1981, 318, 664-666.	6.3	3
282	Adverse Effects of Anti-ulcer Drugs. <i>Drugs</i> , 1981, 21, 444-459.	4.9	31
283	Acute respiratory failure and CNS-depressing drugs.. <i>Postgraduate Medical Journal</i> , 1981, 57, 279-282.	0.9	6
284	The changing pattern of toxicity of digoxin. <i>Postgraduate Medical Journal</i> , 1981, 57, 358-362.	0.9	9
285	Cimetidine and ranitidine in duodenal ulcer.. <i>BMJ: British Medical Journal</i> , 1980, 281, 473-474.	2.4	55
286	Indomethacin and perforated duodenal ulcer.. <i>BMJ: British Medical Journal</i> , 1980, 280, 1088-1089.	2.4	2
287	Cimetidine and ranitidine: comparison of effects on hepatic drug metabolism.. <i>BMJ: British Medical Journal</i> , 1980, 281, 775-777.	2.4	153
288	Severe Hypokalemia in Hospitalized Patients. <i>Archives of Internal Medicine</i> , 1979, 139, 978.	4.3	36

#	ARTICLE	IF	CITATIONS
289	The [14C]â€aminopyrine breath test. A comparison of different forms of analysis.. British Journal of Clinical Pharmacology, 1979, 8, 539-545.	1.1	27
290	Adverse reactions to frusemide in hospital inpatients.. BMJ: British Medical Journal, 1979, 2, 360-362.	2.4	39
291	Severe hypokalemia in hospitalized patients. Archives of Internal Medicine, 1979, 139, 978-980.	4.3	7
292	Failure of 2 h [14C]â€aminopyrine breath test to demonstrate microsomal enzyme induction by glutethimide [proceedings]. British Journal of Clinical Pharmacology, 1978, 6, 460P.	1.1	2
293	DEFECTIVE ABSORPTION OF INJECTED INSULIN. Lancet, The, 1978, 312, 741-742.	6.3	17
294	Jaundice during cyproheptadine treatment.. BMJ: British Medical Journal, 1978, 1, 753-753.	2.4	7
295	Continuous infusion of frusemide in refractory oedema.. BMJ: British Medical Journal, 1978, 2, 476-476.	2.4	45
296	Hyponatraemia during carbamazepine treatment.. BMJ: British Medical Journal, 1977, 1, 83-84.	2.4	60
297	Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"?. BMJ: British Medical Journal, 1977, 1, 691-692.	2.4	38
298	Drug Information Centres: New Role for Pharmacists?. Scottish Medical Journal, 1977, 22, 147-150.	0.7	1
299	Fatal agranulocytosis attributed to co-trimoxazole therapy.. BMJ: British Medical Journal, 1977, 2, 316-316.	2.4	8
300	Drug therapy reviews: Intravenous fluid therapy. American Journal of Health-System Pharmacy, 1977, 34, 1332-1338.	0.5	1
301	Frequency and pattern of radionuclide administration to medical patients in a general hospital. European Journal of Nuclear Medicine and Molecular Imaging, 1977, 2, 133-5.	2.2	0
302	National Medicinal Drug Policies: their Relationship to Pharmacoepidemiology. , 0, , 433-447.		1
303	Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies. , 0, , 37-57.		2
304	Assessing the Impact of the Australia-United States Free Trade Agreement (AUSFTA) on Australian and Global Medicines Policy. SSRN Electronic Journal, 0, , .	0.4	2
305	National Medicinal Drug Policies: Their Relationship to Pharmacoepidemiology. , 0, , 375-390.		0